Evidence map›Paper›PMID 32841042›Full record

ArticleCell transplantation

The Disillusioned Comfort with COVID-19 and the Potential of Convalescent Plasma and Cell Therapy.

Mia C Borlongan, Maximillian C Borlongan, Paul R Sanberg

Abstract readEditorial
In one paragraph

Article in Cell transplantation. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Observational
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Mia C Borlongan1438University of California Berkeley, Berkeley, CA, USA.ORCID 0000-0003-3223-8374
Maximillian C Borlongan7831Tampa Preparatory School, Tampa, FL, USA.
Paul R Sanberg7831University of South Florida, Tampa, FL, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coronavirus disease 2019 or COVID-19 is highly infectious, which can lead to acute and chronic debilitating symptoms, as well as mortality. The advent of safe and effective vaccines or antiviral drugs remains distant in the future. Practical public health measures, such as social distancing, hand washing, and wearing a face mask, are the current recommended guidelines by the Centers for Disease Control and Prevention for limiting the spread of the virus. Weakened immune system and aberrant inflammation represent a major pathological symptom of COVID-19 patients. Based on the unique immunomodulatory properties of both convalescent plasma and stem cells, we discuss here their potential use for treating COVID-19.

Indexed as

Mesenchymal Stem Cell TransplantationAntibodies, NeutralizingBetacoronavirusClinical Trials as TopicCoronavirus InfectionsCOVID-19COVID-19 SerotherapyHumansImmunization, PassiveMesenchymal Stem CellsPandemicsPneumonia, ViralPublic Health PracticeSARS-CoV-2Viral LoadAntibodies, Neutralizingconvalescent plasmaimmunoglobulinmesenchymal stem cellsvaccinevirus

Identifiers

PMID32841042
PMCPMC7563883

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.